## José B Fariña

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1590665/publications.pdf

Version: 2024-02-01

686830 642321 42 629 13 23 citations h-index g-index papers 42 42 42 828 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Development of two high-performance liquid chromatographic methods for the analysis and characterization of insulin and its degradation products in pharmaceutical preparations. Biomedical Applications, 2000, 749, 25-34.	1.7	91
2	Comparative study of protein molecular weights by size-exclusion chromatography and laser-light scattering. Journal of Pharmaceutical and Biomedical Analysis, 2001, 25, 833-841.	1.4	53
3	Potential applications of PLGA film-implants in modulating in vitro drugs release. International Journal of Pharmaceutics, 2002, 248, 149-156.	2.6	50
4	Effect of high shear rate on stability of proteins: kinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2003, 33, 145-155.	1.4	50
5	Stability Study of Human Serum Albumin Pharmaceutical Preparations. Journal of Pharmacy and Pharmacology, 2010, 51, 385-392.	1.2	34
6	Applications of Multi-Angle Laser Light-Scattering Detection in the Analysis of Peptides and Proteins. Current Drug Discovery Technologies, 2004, 1, 229-242.	0.6	32
7	In-vitro release of fluoropyrimidines from PLGA film implants. Journal of Pharmacy and Pharmacology, 2010, 54, 757-763.	1,2	21
8	Structure-Performance Relationships of Temperature-Responsive PLGA-PEG-PLGA Gels for Sustained Release of Bone Morphogenetic Protein-2. Journal of Pharmaceutical Sciences, 2017, 106, 3353-3362.	1.6	20
9	Biodegradable laminar implants for sustained release of recombinant human growth hormone. Biomaterials, 2002, 23, 4759-4764.	5.7	19
10	New Trends in Analysis of Biopharmaceutical Products. Current Pharmaceutical Analysis, 2007, 3, 230-248.	0.3	19
11	Data Analysis of Kinetic Modelling Used in Drug Stability Studies: Isothermal Versus Nonisothermal Assays. Pharmaceutical Research, 2006, 23, 2595-2602.	1.7	17
12	Fitting bevacizumab aggregation kinetic data with the Finkeâ€"Watzky two-step model: Effect of thermal and mechanical stress. European Journal of Pharmaceutical Sciences, 2015, 77, 170-179.	1.9	16
13	An improved methodology for data analysis in accelerated stability studies of peptide drugs: Practical considerations. Talanta, 2012, 94, 158-166.	2.9	14
14	Design and optimization of a child-friendly dispersible tablet containing isoniazid, pyrazinamide, and rifampicin for treating tuberculosis in pediatrics. Drug Development and Industrial Pharmacy, 2020, 46, 309-317.	0.9	14
15	Chromatographic characterization of synthetic peptides: SPf66 malaria vaccine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 766, 3-12.	1.2	13
16	Capability measurement of size-exclusion chromatography with a light-scattering detection method in a stability study of bevacizumab using the process capability indices. Journal of Chromatography A, 2014, 1353, 89-98.	1.8	13
17	Supercritical CO2 technology for one-pot foaming and sterilization of polymeric scaffolds for bone regeneration. International Journal of Pharmaceutics, 2021, 605, 120801.	2.6	13
18	Measurement of uncertainty in peptide molecular weight determination using size-exclusion chromatography with multi-angle laser light-scattering detection and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Analytica Chimica Acta, 2004, 512, 103-110.	2.6	12

#	Article	IF	Citations
19	Development of an ultra high performance liquid chromatography method for determining triamcinolone acetonide in hydrogels using the design of experiments/design space strategy in combination with process capability index. Journal of Separation Science, 2016, 39, 2689-2701.	1.3	12
20	Effectiveness of Antimicrobial Preservation of Extemporaneous Diluted Simple Syrup Vehicles for Pediatrics. Journal of Pediatric Pharmacology and Therapeutics, 2018, 23, 405-409.	0.3	11
21	Development and validation of an UPLC method for determination of content uniformity in low-dose solid drugs products using the design space approach. Talanta, 2013, 115, 490-499.	2.9	10
22	Stability Study of Isoniazid and Rifampicin Oral Solutions Using Hydroxypropyl-Î'-Cyclodextrin to Treat Tuberculosis in Paediatrics. Pharmaceutics, 2020, 12, 195.	2.0	10
23	Pre-study and in-study validation of a size-exclusion chromatography method with different detection modes for the analysis of monoclonal antibody aggregates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1022, 206-212.	1.2	8
24	Formulation design of oral pediatric Acetazolamide suspension: dose uniformity and physico-chemical stability study. Pharmaceutical Development and Technology, 2017, 22, 191-197.	1.1	8
25	Optimization of dl-PLA molecular weight via the response surface method. International Journal of Pharmaceutics, 1992, 86, 107-111.	2.6	7
26	hGH release from directly compressed hGH-PLGA biodegradable implantable tablets: Influence of physicomechanical factors. European Polymer Journal, 2009, 45, 2830-2838.	2.6	7
27	Evaluation of non-isothermal methods in stability studies of human insulin pharmaceutical preparations. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 916-922.	1.4	6
28	Estimation of uncertainty in size-exclusion chromatography with a double detection system (light-scattering and refractive index). Talanta, 2009, 78, 781-789.	2.9	6
29	Pharmacokinetics analysis of sustained release hGH biodegradable implantable tablets using a mouse model of human ovarian cancer. International Journal of Pharmaceutics, 2010, 388, 175-180.	2.6	6
30	Solid-state stability studies of cholecystokinin (CCK-4) peptide under nonisothermal conditions using thermal analysis, chromatography and mass spectrometry. European Journal of Pharmaceutical Sciences, 2010, 39, 263-271.	1.9	6
31	Data analysis in stability studies of biopharmaceutical drugs with isothermal and non-isothermal assays. TrAC - Trends in Analytical Chemistry, 2011, 30, 717-730.	5.8	5
32	Characterization of antimalarial SPf66 peptide using MALDI–TOF MS, CD and SEC. Peptides, 2002, 23, 1527-1535.	1.2	4
33	Development of a novel physico-chemically and microbiologically stable oral solution of flecainide for pediatrics. Pharmaceutical Development and Technology, 2018, 23, 978-985.	1.1	4
34	Statistical assessment of between batch stability equivalence. International Journal of Pharmaceutics, 2000, 204, 61-68.	2.6	3
35	Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer. Endocrine, 2010, 37, 430-439.	1.1	3
36	Safe use of Dexamethasone in pediatrics: design and evaluation of a novel stable oral suspension. Pharmaceutical Technology in Hospital Pharmacy, 2018, 3, 59-70.	0.4	3

#	Article	IF	CITATIONS
37	A High-Demanding Strategy to Ensure the Highest Quality Standards of Oral Liquid Individualized Medicines for Pediatric Use. AAPS PharmSciTech, 2019, 20, 208.	1.5	3
38	Comparison of Shelf-Life Estimates for a Human Insulin Pharmaceutical Preparation Using the Matrix and Full-Testing Approaches. Drug Development and Industrial Pharmacy, 2003, 29, 513-521.	0.9	2
39	Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and hydrogen exchange combined with enzymatic digestion for the structural characterization of antimalaric Spf66 peptide. Talanta, 2007, 72, 1192-1198.	2.9	2
40	Application of a validated stability-indicating chromatographic method to evaluate the reproducibility between batches of small peptides in solution. Analytica Chimica Acta, 2010, 675, 83-90.	2.6	1
41	Impact of storage conditions on a new child-friendly dispersible tablet for treating Tuberculosis in pediatrics Pharmaceutical Sciences, 2021, , .	0.1	1
42	APPLICATION OF THE ICH GUIDELINES IN VALIDATION OF A CHROMATOGRAPHIC METHOD FOR CCK-4 FRAGMENT OF CHOLECYSTOKININ. Journal of Liquid Chromatography and Related Technologies, 2002, 25, 2795-2806.	0.5	0